[{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Hematology","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xspray Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xspray Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xspray Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xspray Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xspray Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xspray Pharma \/ Undisclosed"},{"orgOrder":0,"company":"KeifeRx, LLC","sponsor":"Worldwide Clinical Trials | Life Molecular Imaging | Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Neurology","graph2":"Phase III","graph3":"KeifeRx, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KeifeRx, LLC \/ Worldwide Clinical Trials | Life Molecular Imaging | Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"KeifeRx, LLC \/ Worldwide Clinical Trials | Life Molecular Imaging | Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"KeifeRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Neurology","graph2":"Phase II","graph3":"KeifeRx","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"KeifeRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KeifeRx \/ Undisclosed"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apotex Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Undisclosed"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azurity Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ruta Arays","sponsor":"Novartis Pharmaceuticals Corporation | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Ruta Arays","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ruta Arays \/ Novartis Pharmaceuticals Corporation | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Ruta Arays \/ Novartis Pharmaceuticals Corporation | National Cancer Institute"}]

Find Clinical Drug Pipeline Developments & Deals for Nilotinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Nilotinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 22, 2025

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Nilotinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 22, 2025

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Tasigna-Generic (Nilotinib HCl) is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.

                          Product Name : Tasigna-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 27, 2025

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Danziten (nilotinib), an oral BCR-ABL kinase inhibitor, it is indicated for treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.

                          Product Name : Danziten

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 14, 2024

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 09, 2024

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The agreement aims to to develop and market an anti-cancer drug, Tasigna (nilotinib), a transduction inhibitor, used for treatment of chronic myeloid leukemia.

                          Product Name : Tasigna-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          June 23, 2023

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Aurobindo Pharma Limited

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Proceeds from the financing will advance pipeline of optimized, low dose, orally delivered tyrosine kinase inhibitors including Nilotinib BE for the treatment of multiple neurodegenerative diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 08, 2021

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $6.0 million

                          Deal Type : Series A Financing

                          blank

                          08

                          KeifeRx, LLC

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          KeifeRx, LLC

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Neurology

                          Study Phase : Phase III

                          Sponsor : Worldwide Clinical Trials | Life Molecular Imaging | Sun Pharmaceutical Industries Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nilotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 03, 2021

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Worldwide Clinical Trials | Life Molecular Imaging | Sun Pharmaceutical Industries Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Ruta Arays

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Ruta Arays

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Sponsor : Novartis Pharmaceuticals Corporation | National Cancer Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nilotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 26, 2021

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Novartis Pharmaceuticals Corporation | National Cancer Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Nilotinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 23, 2020

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank